

Beta-Amyloid 1-42 and 1-40 with Ratio (1-42/1-40), Plasma

1-800-533-1710

BAMYP

Patient ID	Patient Name		Birth Date	Sex	Age
SA00172671	TESTING, BAMYP N		1990-08-08	F	34
Order Number SA00172671	Client Order Number SA00172671	Ordering Physician CLIENT,CLIENT	Report Notes	1	1
Account Information C7028846 DLMP Roche	ster	Collected 03 Nov 2024 08:00			

Beta-Amyloid 1-42, 1-40, Ratio, P

Beta-Amyloid 1-42 Plasma	SDL	Alzheimer's disease.	
77 pg/mL		The testing method is a chemiluminesc manufactured by Fujirebio, Inc. and pe	erformed on the Lumipulse
Beta-Amyloid 1-40 Plasma	SDL	analyzer. The beta-Amyloid ratio is calc measurements of the beta-Amyloid 1– 40.	
1000 pg/mL		40.	
Beta-Amyloid Plasma Ratio	SDL	The Lumipulse plasma beta-Amyloid ra must be interpreted in conjunction with	n the patient clinical
0.077 ratio	e Value 0.077	information. This test is not intended as standalone diagnostic assay.	s a screening or
Beta-Amyloid Plasma Ratio Interpret	1) SDL	Values obtained with different assay m	-
A normal plasma beta-Amyloid Ratio $(1-42/1-40)$ of ≥ 0.07 suggestive of a negative (normal) amyloid positron emission tomography (PET) scan result. This result indicates a reduce		different and cannot be used interchan Received: 04 Nov 2024 09:37	Reported: 04 Nov 2024 09:44
likelihood that a patient's cognitive impairment is due to			

Laboratory Notes

(1) This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

SDL Mayo Clinic Laboratories - Rochester Superior Drive 3050 Superior D	ve NW, Rochester MN 55905 Nikola Baumann Ph.D. 24D1040592